FibroGen Inc. (FGEN)’s Financial Results Comparing With Sutro Biopharma Inc. (NASDAQ:STRO)

As Biotechnology businesses, FibroGen Inc. (NASDAQ:FGEN) and Sutro Biopharma Inc. (NASDAQ:STRO), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FibroGen Inc. 212.96M 19.41 86.42M -0.88 0.00
Sutro Biopharma Inc. 38.42M 6.96 35.32M -2.21 0.00

In table 1 we can see FibroGen Inc. and Sutro Biopharma Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
FibroGen Inc. -40.58% -22.3% -12.8%
Sutro Biopharma Inc. -91.93% 0% 0%

Liquidity

The current Quick Ratio of FibroGen Inc. is 6.8 while its Current Ratio is 6.8. Meanwhile, Sutro Biopharma Inc. has a Current Ratio of 3.5 while its Quick Ratio is 3.5. FibroGen Inc. is better positioned to pay off its short-term and long-term debts than Sutro Biopharma Inc.

Analyst Recommendations

In next table is shown FibroGen Inc. and Sutro Biopharma Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
FibroGen Inc. 0 1 4 2.80
Sutro Biopharma Inc. 0 0 0 0.00

The upside potential is 47.38% for FibroGen Inc. with average price target of $71.2.

Institutional and Insider Ownership

Roughly 67.3% of FibroGen Inc. shares are held by institutional investors while 75.3% of Sutro Biopharma Inc. are owned by institutional investors. FibroGen Inc.’s share held by insiders are 4.3%. Comparatively, insiders own roughly 8.5% of Sutro Biopharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
FibroGen Inc. 0.27% 3.42% 36.27% -3.63% 6.81% 26.82%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year FibroGen Inc. was more bullish than Sutro Biopharma Inc.

Summary

On 8 of the 11 factors FibroGen Inc. beats Sutro Biopharma Inc.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.